Consolidated Statements of Cash Flows (Parenthetical) (USD $)	1 Months Ended
	Oct. 21, 2011 Roche	Apr. 30, 2012 Alvos acquisition	Mar. 23, 2005 Insert Therapeutics, Inc	Feb. 28, 2010 Calando Pharmaceuticals, Inc.	Sep. 30, 2009 Calando Pharmaceuticals, Inc.	Mar. 31, 2006 Calando Pharmaceuticals, Inc.	Sep. 30, 2010 Calando Pharmaceuticals, Inc. Series A Preferred Stock	Apr. 23, 2008 Unidym, Inc.	Apr. 29, 2008 MASA Energy LLC
Purchase of common shares			7,375,000	200,000	2,850,000	964,000	1,562.5	200,000
Common stock, shares issued			50,226	8,000	114,000	20,838		7,054	10,504
Common stock value			$ 2,000,000		$ 706,800	$ 1,077,333			$ 310,000
Value of common stock purchased						1,928,000			560,000
Stock purchased by cash				60,000		850,667		200,000	250,000
Warrants issued				2,400	24,000		390,625
Warrants purchased					600,000
Common stock exercise value				$ 5.00			$ 5.00
Shares exchanged as part of acquisition	1,288,158	315,457
Issue of promissory note to Roche	$ 50,000